NEW YORK, May. 1 - Incyte Genomics today posted a wider first-quarter loss and blamed falling subscription and licensing revenue.
Revenue fell to $29 million from $51 million after the firm discontinued its custom genomic product lines last October, the company said.
R&D spending in the quarter ended March 31 fell to $33.6 million from almost $53 million one year ago, though net loss managed to inch higher to $13.4 million, or $.20 per diluted share, compared to $10.3 million, or $.16 a share, year over year.
Incyte said it had just under $100 million in cash and cash equivalents as of March 31.
Click here for more information.